Clinical Trials
12 trialsNCT04972097 2026-06-02
PRESERVE
Angiodynamics, Inc.
Phase NA Completed
NCT03603808 2026-05-08
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
AIDS Malignancy Consortium
Phase 2 Completed
NCT05345444 2026-03-25
RTIRE
Weill Medical College of Cornell University
Phase NA Active not recruiting
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT06378047 2026-02-09
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT07328243 2026-01-09
IRE-TCLN
First Affiliated Hospital of Zhejiang University
Phase NA Recruiting
NCT07306273 2025-12-29
IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Ruijin Hospital
Phase 2 Recruiting
NCT06451445 2025-12-11
WIRED
University Health Network, Toronto
Phase NA Recruiting
NCT03484299 2025-10-29
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
Phase 1 Recruiting
NCT07191548 2025-10-10
LIVERMET-IRE
Angiodynamics, Inc.
Phase NA Not yet recruiting
NCT07192731 2025-10-10
LIVERHCC-IRE
Angiodynamics, Inc.
Phase NA Not yet recruiting
NCT06205849 2025-07-25
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
University of California, San Diego
Phase 1 Recruiting